er than in previous Scandinavian studies. Men are at higher risk than women. The proportion with warfarin-associated ICH is higher than previously reported from Scandinavia.
Introduction
Scandinavian data on the incidence and outcome of intracerebral hemorrhage (ICH) are scarce. We have found no published data from the last decade on sex-and age-specific incidences, the proportional distribution of hematoma locations or the proportion with ICH associated with oral anticoagulant treatment (OAT) with warfarin (OAT-ICH).
In a recent European multi-population study the annual incidence of ICH per 100,000 adjusted to the standard European population was 16.9 in men and 12.4 in women in [2004] [2005] [2006] , but there was considerable variation between different European regions [1] . In Italy in 1994-1998 a crude annual incidence rate for a first-ever ICH was 36.9 per 100,000. When standardized to the 2006 European population it was 32.9 per 100,000 [2] . In a study from southern Sweden, the incidence per 100,000 in 1996 was 30.0 (crude) and 20.6 (adjusted to the Euro-ICH in Southern Norway -A Hospital-Based Incidence Study Eur Neurol 2012; 67:240-245 241 pean standard population) [3] . In Norway published incidence data are limited to one study of stroke epidemiology in mid-Norway in 1994-1996 with only 55 cases of ICH. The crude annual incidence was 32. Sex distribution and adjustment to the standard European population were not reported [4] .
Demographic composition and risk factors vary between regions and over time. Time trends in the incidence of ICH are unclear. The incidence of ischemic stroke has decreased in high-income countries in the last four decades, but it is unclear whether the incidence of ICH has fallen [5] . Previous studies have suggested a variation in stroke incidence within Scandinavia, and a south-north gradient has been suggested with higher stroke incidence in mid-and northern Scandinavia and a lower incidence in southern Scandinavia [6] . This has not been assessed specifically for ICH.
The 30-day case fatality rate (CFR) in ICH is higher than in ischemic stroke ranging from 25-35% in a systematic review of population-based studies [1] .
OAT-ICH has a particularly high early mortality in several studies [7] [8] [9] [10] . In Scandinavia this has been assessed in a Swedish study from 1993-2000 where CFR was not significantly increased in OAT-ICH compared to non-OAT-ICH [11] . Warfarin use for stroke protection in atrial fibrillation is increasing, particularly in the elderly. Newer European data on the frequency and prognosis of OAT-ICH, however, are scarce. In a study from southern Sweden OAT-ICH accounted for 12% of all ICH in 1996. The CFR was not reported [3] . New oral anticoagulants are currently being launched. Updated data on OAT-ICH in unselected populations are therefore needed.
The aim of the present study was to provide updated community-based data from southern Norway on incidence, baseline characteristics, and 30-day case fatality of ICH leading to hospitalization.
Material and Methods
We used a well-defined catchment area with 152,000 inhabitants, in the southernmost region of Norway, from which all patients with acute stroke are admitted to the Department of Neurology at Sørlandet Sykehus Kristiansand (SSK). Emergency medical services, primary care and nursing homes collaborate closely with SSK with a low threshold policy of immediate hospitalization of all stroke patients regardless of age and severity. The study data set contains all consecutive patients hospitalized with a first-ever ICH in the five-year period [2005] [2006] [2007] [2008] [2009] . We screened the hospital register for all in-and outpatients with International Classification of Disease 10 (ICD 10) codes I61, I62 and I64. One of the authors (A.T.) assessed all CT images for the purpose of the study.
We excluded traumatic ICH, ICH related to intracranial malignant tumor, extracerebral intracranial hemorrhage and ICH related to thrombolytic treatment. Cases with isolated intraventricular hemorrhage without visible affection of cerebral parenchyma were excluded. Patients from the study area who were hospitalized elsewhere with ICH and subsequently transferred to SSK were included.
Risk factors, clinical, and radiological data were recorded in a stroke register from September 2007 and retrieved from patient files in cases prior to that. We recorded living arrangements, current and previous smoking, hypertension (defined as medically treated or a known diagnosis in the patient record), diabetes mellitus (defined as known diagnosis in the patient record) and coronary heart disease (defined as having had an acute myocardial infarct, coronary bypass surgery or percutaneous coronary intervention), and medication (aspirin, clopidogrel, dipyridamole, warfarin, statins, antihypertensives and antidiabetics). Hospitalization within 3 h of symptom onset was recorded. Death was automatically updated monthly through a linkage to the National Population Register [12] .
All patients had a non-contrast CT scan at baseline. Hematoma location was classified as lobar (predominantly cortical or subcortical white matter), deep cerebral, brainstem or cerebellum. Hematoma volume was calculated with the A ! B ! C/2 formula [13] . Presence of intraventricular blood was registered.
The cause of hemorrhage was identified when possible. Hypertension was defined as the cause if there was a known history of hypertension, and no other identified cause.
Descriptive statistics were used to summarize the number of patients and baseline characteristics, Chi square for comparisons of categorical, a t test for continuous parametric and Mann-Whitney for nonparametric variables. For calculation of incidence we used the population on January 1st of the midyear 2007 giving 761,135 person years at risk [14] . We created age groups by every ten years starting with 45-54 years. Patients younger than 45 years were pooled since ICH is rare in this age group [5] .
We calculated the crude incidence rate for each sex in each age group and the total incidence adjusted to the standard European population for each sex and both sexes. For all rates we calculated the 95% Poisson confidential interval (95% CI). The MantelHaenszel test was used to estimate the overall rate ratio men/ women. p values of less than 0.05 were considered statistically significant. Statistical analysis was performed with SPSS version 18. We used logistic regression to compare CFR in OAT-ICH and non-OAT-ICH adjusting for age, sex, warfarin and Glasgow Coma Scale (GCS) score.
The study was approved by the regional committee of medical research ethics (REK).
Results
In total, 197 patients were hospitalized with nontraumatic ICH. Sixty-three patients were excluded by one or more exclusion criteria, the most frequent of which were address outside the defined catchment area (n = 26), presence of intracranial malignant tumor (n = 14) and the event being a recurrent ICH (n = 10). Three cases with isolated intraventricular hemorrhage were excluded. In the study period a total of 1,587 patients were hospitalized with stroke, 1,390 of which were ischemic, giving 12.4% nontraumatic ICH of total stroke. All cases had head scans.
The number of first-ever in a lifetime ICH included for analysis was 134. All were hospitalized. None were found amongst outpatients. A control CT was taken in 47% of all patients and in 65% of those surviving 7 days. An MR was taken in 33% of all and 46% of those surviving 7 days.
Incidence
The crude annual incidence rate was 17.6 per 100,000 per year. Adjusted to the standard European population it was 12.5 per 100,000 per year. Incidence rates are listed by sex and age groups in table 3 . The overall age-adjusted rate ratio men/women analyzed with the Mantel-Haenzel test was 1.78 (p = 0.001). The age-adjusted incidence in Kristiansand and six European regions studied by the European Registers of Stroke (EROS) are presented together in table 4 .
Hematoma Location
The proportional distribution of hematoma locations is shown in total and for each sex in table 2 . The median ICH volume (interquartile range, IQR, in parentheses) was larger in lobar, 27 ml (8-82), than in deep cerebral hematomas, 15 ml (5.3-54.3), but this was not statistically significant (p = 0.161). Intraventricular hemorrhage (50.8 vs. 24.5%, p = 0.005), hypertension (68.9 vs. 30.4%, p ! 0.001) and current smoking (32.1 vs. 15.2%, p = 0.039) were more frequent in deep cerebral than lobar hematomas. There was no difference between deep cerebral and lobar location regarding sex, age, or frequency of coronary heart disease, atrial fibrillation, diabetes mellitus or previous TIA or stroke.
OAT-ICH
The proportion with OAT-ICH was 26.9%. The annual incidence of OAT-ICH was 4.7 (95% CI 3.4-6.5) per 100,000. The median international ratio (INR) was 2.6 (IQR 2.2-2.9). Only 2 patients (5.6%) had an INR of more than 4. The cause for taking warfarin was atrial fibrillation in 30 of 36 patients (83.3%), deep venous thrombosis/ pulmonary embolism in 3 (8.3%) and other in 3 (8.3%). Four of the 36 OAT-ICH patients were on dual therapy with warfarin and aspirin (11.1%), one (2.8%) on dual therapy with warfarin and clopidogrel, one (2.8%) on triple therapy with warfarin, aspirin and clopidogrel. Warfarin users were older than nonusers (78.6 vs. 74.0 years, p = 0.054) and more often had hypertension (70.6 vs. 49.0%, p = 0.029), atrial fibrillation (83.3 vs. 5.1%, p ! 0.001) and a previous TIA or ischemic stroke (33.3 vs. 16 .3%, p = 0.032). The median ICH volume was 25 ml (IQR 13-68) in warfarin users vs. 17 ml (IQR 5-39) in nonusers (p = 0.065).
Hypertension was identified as the cause in 41.9% of men, 31.7% of women (p = 0.224) and 37.3% in total. An arteriovenous malformation was found in 3 patients (2.2%) and a cavernoma in 2 (1.5%). 
30-Day Case Fatality Rate
The overall 30-day CFR was 36.6%. There was no statistically significant difference between men and women (40.5 vs. 31.7%, p = 0.289). Of the 49 deaths seen within 30 days, 31 (63%) occurred within two days and 40 (84%) within seven days. CFR was 61.1% in the 36 patients on warfarin versus 27.6% in the 99 not using warfarin (p ! 0.001). Multivariate analysis showed that CFR was associated with GCS score (OR 16.6, p ! 0.001) and warfarin (OR 4.3, p = 0.015), but not with age and sex.
The discharge destination was the patient's home in 25 patients (18.7%), rehabilitation unit in 42 (31.3%), nursing 
Discussion
Our study showed an age-adjusted ICH incidence of 12.5 per 100,000, which is in the midrange of the findings in a multipopulation study by the EROS Investigators [1] . The age-adjusted rate in our study was higher in men than women. This was also found in five of the six regions in the EROS study (all regions but Dijon, France) [1] .
Prior to our study the only published Norwegian incidence data on ICH showed a crude annual incidence of 32 (23-43) per 100,000 [4] . In southern Sweden a crude incidence of 30.0 (26.9-33.3) per 100,000 was found for the year 1996 [3] . Our study, approximately 10-13 years later, may reflect regional differences within Scandinavia or a time trend. However, differences must be interpreted with caution due to small numbers and methodological differences between studies. In the Swedish study neither bleeding in tumor nor recurrent incidents were excluded.
The incidence in our study increased with age through all age groups in both sexes. Some studies including the only two Scandinavian ones with age-specific incidence, have shown a decreasing incidence in the highest age group [3, 4] . In a recent systematic review of incidence studies the authors suggested that possible explanations for the decrease in the highest age group in some studies can be incomplete case finding and stroke subtype classification [5] .
The proportion of patients with OAT-ICH (26.9%) was higher in our study than in most reports. More than 80% of those using warfarin in our study used it due to atrial fibrillation. Most cases of OAT-ICH occurred with therapeutic levels of the INR, which is in line with a Swedish cohort study from 1993-1998 [15] . In a recent review it is estimated that approximately 1% of the population in Europe is receiving OAT with up to 1.7% in some countries [16] . In the Norwegian Prescription Database the proportion of registered users in 2009 was 2.1% in Vest-Agder County, which covers most of the study area. The proportion increased steeply with increasing age to 16.8% in the age group 80-89 years [17] . After completion of our study, a large study from Finland was published showing 18% OAT-ICH with a 28-day CFR of 54.4%. Like in our study most cases occurred with an INR in a therapeutic level [18] . Compared with our study the patients in the Finnish study had a lower mean age (74.4 vs. 78.6 years). Warfarin use in the total population (2.3%) was almost identical to ours, but the use in the highest age group was not specified. Our annual incidence of OAT-ICH of 4.7 (95% CI 3.4-6.5) per 100,000 is well within an estimate of 2-9 per 100,000 in a review from 2006. [19] However, the relative proportion of OAT-ICH of total ICH is higher in our study than in most reports.
We believe our findings reflect an increasing proportion of OAT-ICH linked to an increased use of warfarin in elderly patients with atrial fibrillation.
The overall 30-day CFR of 36% is in line with previous reports. Consistent with other studies the CFR was particularly high in OAT-ICH [7] [8] [9] [10] . Warfarin users are older and have more risk factors than nonusers. The impact of warfarin itself on the occurrence and clinical course of ICH therefore needs cautious interpretation. However, warfarin use was independently associated with death at thirty days when adjusted for age, sex and GCS score.
The proportional distribution of hematoma locations was similar to findings in Greater Cincinnati (USA), Jyvaskyla (Finland) and Perth (Australia). Other European community-based data have shown conflicting proportional distributions [20] . We found somewhat larger hematomas in men than women.
Hospital admission within three hours of symptom duration was seen in 41% of the patients. This proportion is rarely reported in community-based series. We find it relevant in the light of emerging acute treatments for ICH. The proportion arriving early may be higher in ICH than in ischemic stroke. In a previous study in our center, 23% of all patients with ischemic stroke arrived at the hospital within three hours [21] .
A strength of our study is the simple setting with community-based catchment and all cases of ICH leading to hospitalization. A further strength compared to many epidemiological studies is a detailed assessment of neuroimages in all cases. A limitation is the possibility of having lost some cases that were not hospitalized. However, since the diagnosis of ICH requires either neuroimaging or autopsy we believe that the number of verifiable cases lost was low. The findings that the number of incidents per year showed little variation, and that the incidence increased with age including the highest age group also indicate that few cases were lost.
In conclusion this study shows an incidence of ICH in the European midrange with an excess of men in all age groups. The incidence is lower than in previous Scandinavian reports and the proportion of patients on oral anticoagulant therapy with warfarin is higher.
